- Home
- DHIL vs AQST Comparison
DHIL vs AQST Comparison
Compare DHIL & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHIL
- AQST
- Stock Information
- Founded
- DHIL 1990
- AQST 2004
- Country
- DHIL United States
- AQST United States
- Employees
- DHIL N/A
- AQST N/A
- Industry
- DHIL Investment Managers
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- DHIL Finance
- AQST Health Care
- Exchange
- DHIL Nasdaq
- AQST Nasdaq
- Market Cap
- DHIL 392.1M
- AQST 390.4M
- IPO Year
- DHIL 1995
- AQST 2018
- Fundamental
- Price
- DHIL $133.40
- AQST $3.82
- Analyst Decision
- DHIL
- AQST Strong Buy
- Analyst Count
- DHIL 0
- AQST 7
- Target Price
- DHIL N/A
- AQST $11.29
- AVG Volume (30 Days)
- DHIL 33.9K
- AQST 1.1M
- Earning Date
- DHIL 07-29-2025
- AQST 08-12-2025
- Dividend Yield
- DHIL 4.50%
- AQST N/A
- EPS Growth
- DHIL 21.42
- AQST N/A
- EPS
- DHIL 17.58
- AQST N/A
- Revenue
- DHIL $151,281,009.00
- AQST $54,228,000.00
- Revenue This Year
- DHIL N/A
- AQST N/A
- Revenue Next Year
- DHIL N/A
- AQST $51.62
- P/E Ratio
- DHIL $7.59
- AQST N/A
- Revenue Growth
- DHIL 6.29
- AQST 5.29
- 52 Week Low
- DHIL $122.32
- AQST $2.12
- 52 Week High
- DHIL $173.25
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- DHIL 27.54
- AQST 49.06
- Support Level
- DHIL $151.00
- AQST $3.85
- Resistance Level
- DHIL $152.03
- AQST $4.10
- Average True Range (ATR)
- DHIL 3.66
- AQST 0.23
- MACD
- DHIL -2.48
- AQST -0.07
- Stochastic Oscillator
- DHIL 4.60
- AQST 12.26
About DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.